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ABSTRACT  56	
Background: Riboflavin is required for several redox reactions. Clinical riboflavin 57	
deficiency occurs mainly in low-income countries, where it is associated with anemia. 58	
The functional significance of suboptimal riboflavin status in different populations and its 59	
role in anemia is not well understood. 60	
Objectives: We assessed biomarker status of riboflavin and its association with 61	
hemoglobin concentration and anemia in women living in Vancouver, Canada and Kuala 62	
Lumpur, Malaysia. 63	
Methods: Healthy non-pregnant, non-breastfeeding women (19-45 years) were recruited 64	
from Canada (n=206) and Malaysia (n=210) via convenience sampling. Fasting blood 65	
was collected to assess riboflavin status (erythrocyte glutathione reductase activity 66	
coefficient, EGRac), hematological indicators, soluble transferrin receptor (sTfR), 67	
ferritin, vitamin A, folate, and vitamin B-12 concentrations. Linear and logistic 68	
regression models were used to assess the association of riboflavin status with 69	
hemoglobin concentration and anemia. 70	
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Results: EGRac (mean±SD) values were higher, indicating poorer riboflavin status, in 71	
Malaysian versus Canadian women, 1.49±0.17 vs. 1.38±0.11. Likewise, riboflavin 72	
biomarker deficiency (EGRac ≥1.40) was significantly more prevalent among Malaysians 73	
than Canadians (71% vs. 40%). More Malaysian than Canadian women were anemic 74	
(hemoglobin <120 g/L; 18% vs. 7%). Using linear regression (pooled sample; n=416), 75	
EGRac values were negatively associated with hemoglobin concentration (r= -0.18; P 76	
<0.001). This relationship remained significant (P =0.029) after adjusting for age, parity, 77	
ethnicity, vitamin B-12, folate, sTfR, ferritin, and vitamin A. Women with riboflavin 78	
deficiency (EGRac ≥1.40) were twice as likely to present with anemia (adjusted OR= 79	
2.38, 95% CI: 1.08, 5.27) compared to women with EGRac <1.40. 80	
Conclusions: Biochemical riboflavin deficiency was observed in Canadian and 81	
Malaysian women, with higher rates of deficiency among Malaysian women. Deficient 82	
biomarker status of riboflavin was a weak but significant predictor of hemoglobin and 83	
anemia suggesting that the correction of riboflavin deficiency may potentially play a 84	
small protective role in anemia, but this requires further investigation.   85	
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INTRODUCTION   89	
 Riboflavin, as flavin adenine dinucleotide (FAD) and flavin mononucleotide 90	
(FMN), is an important enzymatic cofactor in several redox reactions. It is primarily 91	
obtained from dairy products, beef, chicken, fish, and in some countries, fortified wheat 92	
flour (1). Severe riboflavin deficiency (intakes of 0.5-0.6 mg/day in adults), which is 93	
uncommon in high-income countries, leads to clinical signs of deficiency such as 94	
cheilosis, angular stomatitis, and colored-swollen tongue (1). Milder forms of riboflavin 95	
deficiency, defined as the presence of biomarker deficiency without overt clinical 96	
deficiency symptoms (1), have been associated with anemia (2,3), which is more 97	
common in women (4). It is hypothesized that riboflavin deficiency impairs red blood 98	
cell synthesis by altering flavin-dependent release of iron from stores, decreasing iron 99	
absorption, and increasing the rate of iron loss from the gastrointestinal tract (2,5–7). In 100	
addition, riboflavin deficiency could affect hemoglobin production through impaired 101	
flavin-dependent synthesis of 5’pyridoxal phosphate that is required for the first step in 102	
heme biosynthesis (1,8). Most population studies of riboflavin deficiency and anemia 103	
have been conducted in regions with endemic riboflavin deficiency and inadequate 104	
intake, such as in rural Gambia, Thailand, and China (3,9–11). Less is known about 105	
populations with milder forms of riboflavin deficiency. One exception is the study of 106	
Powers et al.(2) in the United Kingdom (UK), which reported that riboflavin 107	
supplementation (2 or 4 mg/day) was associated with a median increase of 4.5g/L in 108	
hemoglobin concentrations among non-pregnant, non-lactating women in the lowest 109	
tertile of riboflavin status at baseline (erythrocyte glutathione reductase activity 110	
coefficient, EGRac >1.65) compared to supplemented women in the first and second 111	
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tertiles (EGRac <1.51 and 1.51-1.65, respectively). EGRac is considered to be the gold-112	
standard measurement of biomarker status of riboflavin. It is a functional indicator of 113	
riboflavin status, whereby the activity of erythrocyte glutathione reductase, an FAD-114	
dependent enzyme, is measured in red blood cells before and after the addition of FAD. 115	
EGRac is a ratio of enzyme activity after FAD addition to enzymatic activity before FAD 116	
addition. A higher EGRac indicates less endogenous FAD available for the enzyme, and 117	
poorer riboflavin status. Although EGRac >1.40 generally equates with deficiency, 118	
EGRac values between >1.20 and >1.70 have been previously used to define low status 119	
(2,9,12–14). 120	
Unlike other B vitamins (e.g. folate and vitamin B-12), biomarker status of 121	
riboflavin is rarely measured in population studies. However, a report from the National 122	
Diet and Nutrition Surveys (NDNS) from the UK reported that 53% of women (aged 19-123	
49 years) had biomarker evidence of riboflavin deficiency (EGRac >1.40) (15) although 124	
only 9.3% of the women consumed less than the UK Lower Reference Nutritional Intake 125	
for riboflavin of 0.8 mg/day (16). In Canada, where white wheat flour is fortified with 126	
riboflavin (17), the prevalence of inadequate riboflavin intake is very low, with less than 127	
5% of women of reproductive age consuming less than the estimated average requirement 128	
(EAR) of 0.9 mg/day (18,19). However, in our recent small study in Vancouver, we 129	
found that 41% of women of reproductive age (n=49) had riboflavin biomarker 130	
deficiency (based on EGRac ≥1.4) (20). 131	
The objectives of this study were to assess riboflavin biomarker status using 132	
EGRac and to determine the relationship between EGRac and hemoglobin concentration 133	
and anemia prevalence in a sample of women of reproductive age from Metro 134	
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Vancouver, Canada and Kuala Lumpur, Malaysia. Canada is a high-income country with 135	
mandatory riboflavin fortification and adequate riboflavin intake, but there is lack of 136	
evidence on the riboflavin status of women of reproductive age in this population; 137	
Malaysia is a middle-income country with no mandatory riboflavin fortification (21) and 138	
reported inadequate riboflavin intake, as well as low dairy consumption (22–24). To 139	
examine ethnic-specific differences in biomarker status, we assessed women of European 140	






 Convenience samples of women (19-45 years) from Metro Vancouver, Canada, 147	
and from Kuala Lumpur, Malaysia, were recruited through posters, e-mails, and 148	
advertisement in the social media. Women were eligible if they were healthy, not 149	
pregnant or breastfeeding, not taking riboflavin-containing supplements for the past four 150	
months, and were of European or Chinese ethnicity (Canada) or Malay or Chinese 151	
ethnicity (Malaysia). Women who self-reported having β-thalassemia, untreated 152	
hypothyroidism, or glucose 6-phosphate dehydrogenase (G6PD) deficiency were 153	
excluded (25–27). To account for the possibility of a significant interaction between 154	
ethnicity and EGRac on hemoglobin concentrations, we aimed to recruit n=100 women 155	
from each ethnic group from each country based on consultation with a biostatistician 156	
using G*Power 3.1 for multiple linear regression (6 independent variables) and an 157	
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expected multiple regression coefficient of R2 = 0.13 with 80% power and 95%CI. Ethics 158	
approval was obtained from the University of British Columbia Clinical Research Ethics 159	
Board in Canada [H15-00521] and from the Medical Research Ethics Committee of the 160	
Faculty of Medicine and Health Sciences, Universiti Putra Malaysia [FPSK(FR15)P020]. 161	
Written informed consent was obtained from all women.  162	
 163	
Data and blood collection 164	
 Women attended a morning clinic following a 10-hour fast. Health and 165	
demographic information was collected using a questionnaire. Body weight, height, and 166	
waist circumference were measured in duplicate using standardized techniques (28). 167	
Venous blood samples were collected into three evacuated tubes (Becton Dickinson), two 168	
with EDTA and one without anticoagulant. A complete blood count was performed on 169	
fresh EDTA blood using hematology analyzers (Beckman COULTER® Ac·T diff™ 170	
Analyzer in Malaysia and Sysmex XT2000i in Canada) and appropriate quality controls 171	
were run daily. Blood samples were spun in a refrigerated (4°C) centrifuge; plasma or 172	
serum were removed and divided into aliquots. Erythrocytes from a tube containing 173	
EDTA were washed three times with PBS (SIGMA), for the EGRac assay. All samples 174	
were shipped on dry ice and stored at -80°C until analyzed. 175	
 176	
Biochemical analyses 177	
 EGRac was measured at Ulster University, Coleraine, Northern Ireland, UK, 178	
using established methods on Randox Daytona+ clinical chemistry analyzer (Randox 179	
Laboratories) (9). EGRac was calculated as the ratio of FAD-stimulated to -unstimulated 180	
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enzyme activity, which indicates the degree of sample saturation with riboflavin (9,29). 181	
Quality control was provided by repeated analysis of stored aliquots of pooled and 182	
characterized erythrocytes, with known EGRac values corresponding to adequate and 183	
deficient status. To adjust for confounding effects of micronutrient deficiencies and 184	
inflammation on hematologic status, the following parameters were measured: indicators 185	
of iron status, folate, vitamin B-12, vitamin A [retinol binding protein (RBP)], C-reactive 186	
protein (CRP), and α-1 acid glycoprotein (AGP). Serum ferritin, soluble transferrin 187	
receptor (sTfR), RBP, CRP, and AGP were assessed by sandwich ELISA at the VitMin 188	
Laboratory (30). Plasma folate concentrations were quantified by a microbiological assay 189	
using 96-microtitre plates and the chloramphenicol-resistant strain of Lactobacillus 190	
rhamnosus (ATCC 27773) at the Trace Elements Lab in the University of Otago, New 191	
Zealand (31,32). Plasma vitamin B-12 was analyzed by competitive immunoassay using 192	
direct chemiluminescent technology at Vancouver General Hospital Chemistry lab 193	
(Siemens ADVIA Centaur, Erlangen, Germany).  194	
For EGRac analysis, the inter-assay CVs were 2.3% for the high control sample 195	
(high riboflavin; mean±SD EGRac: 1.17±0.03) and 2.7% for the low control sample (low 196	
riboflavin; mean±SD EGRac: 1.42±0.04). Inter-assay CVs for the folate assay were 197	
calculated for the concentration of high, medium, and low control samples and were 198	
<15% (12.87%, 6.58%, 9.37%, respectively). For ferritin, sTfR, RBP, CRP, and AGP, 199	
inter-assay CVs were 2.25%, 3.59%, 3.61%, 5.84%, and 8.09%, respectively.  200	
 201	
Statistical analyses  202	
	 10	
  Results are presented as frequencies (%) for categorical variables, mean± SD for 203	
normally distributed continuous variables, and median (IQR) for non-normally 204	
distributed continuous variables. Country- and ethnic-specific differences were 205	
determined by independent sample T-tests (for parametric) and Wilcoxon-rank sum tests 206	
(for non-parametric) to compare concentrations of biomarkers (continuous variables) and 207	
Fischer’s exact tests were used to compare prevalence rates across groups. Ferritin and 208	
RBP concentrations were corrected for inflammation using the inflammation biomarkers, 209	
CRP and AGP (33,34).  210	
 Riboflavin status was classified as deficient (EGRac ≥1.4), suboptimal (1.3≤ 211	
EGRac <1.4), and adequate (EGRac <1.3) (13,29,35). Anemia was defined as 212	
hemoglobin <120 g/L (36). Depleted iron stores were defined as ferritin <15 µg/L, and 213	
tissue iron deficiency was defined as sTfR >8.3 mg/L (36). Acute inflammation was 214	
defined as CRP >5 mg/L and chronic inflammation as AGP >1 g/L (33). Plasma folate 215	
status was categorized as deficient (<6.8 nmol/L), possible deficiency (6.8-13.4 nmol/L), 216	
normal (13.5-45.3 nmol/L), and high (>45.3 nmol/L) (37). Vitamin B-12 status was 217	
classified into adequate (>220 pmol/L), marginal (148-220 pmol/L), and deficient (<148 218	
pmol/L) categories (38,39). 219	
 Linear regression was used to assess the association between hemoglobin 220	
concentration and multiple independent variables. We included interaction terms for 221	
EGRac by country and by ethnicity in the models in order to explore whether country or 222	
ethnicity modified the relationship between EGRac and hemoglobin concentrations. 223	
There were no significant interactions (P >0.05) between EGRac and country or EGRac 224	
and ethnicity on hemoglobin concentrations. We decided a priori, regardless of an 225	
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interaction, to examine each country separately. Variables were included in the model if 226	
they had a bivariate correlation of P ≥ 0.2 with hemoglobin or if they are known to be 227	
associated with anemia. Age, ferritin, RBP, sTfR, vitamin B-12, and folate were analyzed 228	
as continuous variables and parity (≥ 1 child born, yes/no) and ethnicity as categorical 229	
variables in the regression models. Logistic regression models were used to determine the 230	
association between anemia (binary outcome) and EGRac (continuous variable) or 231	
riboflavin deficiency (categorical variable). A maximum of 5 independent variables were 232	
included in the logistic regression models as anemia cases in the total sample were n=53 233	
(40). Significance was indicated by two-sided P values of <0.05. Data were analyzed 234	
using Stata software version SE/14.2 for Mac (Stata Corp, College Station, Texas).  235	
 236	
RESULTS  237	
 We recruited n=110 women of European ethnicity and n=96 women of Chinese 238	
ethnicity living in Metro Vancouver, Canada, and n=105 women of Malay ethnicity and 239	
n=105 of Chinese ethnicity living in Kuala Lumpur, Malaysia. Demographic and 240	
anthropometric characteristics are presented by country and ethnicity in Table 1. Women 241	
from both countries were comparable in age, smoking status, education level, and 242	
prevalence of acute (CRP >5mg/L) and chronic (AGP >1g/L) inflammation. More 243	
Malaysian women had children and the prevalence of overweight/obesity (BMI ≥25 244	
kg/m2) was higher among Malaysian than Canadian women. In Canada, women of 245	
Chinese ethnicity were younger and had a lower prevalence of overweight/obesity than 246	
women of European ethnicity. In Malaysia, women of Chinese ethnicity were younger, 247	
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were less likely to have children, and had lower prevalences of overweight/obesity and 248	
acute inflammation than women of Malay ethnicity. 249	
 Mean hemoglobin concentrations were not different between Canadian and 250	
Malaysian women (Table 2). In Malaysia, women of Chinese ethnicity had higher 251	
hemoglobin concentrations than Malay women. The prevalence of anemia (hemoglobin 252	
<120g/L) was higher in Malaysian women compared to Canadian women. Compared to 253	
Canadian women, EGRac values were higher and riboflavin biomarker deficiency 254	
(EGRac ≥1.4) was more prevalent in Malaysian women.  255	
 Although serum ferritin and the prevalence of depleted iron stores (ferritin <15 256	
µg/L) did not differ between Canadian and Malaysian women, more Malaysian women 257	
had tissue iron deficiency (sTfR >8.3 mg/L) than Canadian women. There was no 258	
biochemical evidence of vitamin A deficiency (RBP <0.7μmol/L), plasma folate 259	
deficiency (<6.8 nmol/L), or macrocytic anemia (hemoglobin <120 g/L and mean 260	
corpuscular volume (MCV) >98 fL). Less than 1% of women had vitamin B-12 261	
deficiency (<148 pmol/L) in both countries. However, more Canadian women had 262	
marginal vitamin B-12 status and high plasma folate concentration (>45.3 nmol/L) than 263	
Malaysian women.   264	
 Few ethnic-specific differences in micronutrient status in women from each 265	
country were observed (Table 2). In Canada, European women had higher EGRac values 266	
and were less likely to be classified as adequate; they also had lower median plasma 267	
vitamin B-12 concentrations and higher serum RBP compared to Chinese women. In 268	
Malaysia, Malay women had higher mean EGRac values, lower median plasma folate 269	
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concentrations, and higher median plasma vitamin B-12 concentrations compared to 270	
Chinese women (Table 2). 271	
 An inverse relationship between hemoglobin concentrations and EGRac was 272	
observed in the entire population of women (r= -0.18; P <0.001). Further, multivariable 273	
linear regression analyses found that a 1-SD increase in EGRac was associated with a 274	
0.10-SD decrease in hemoglobin concentrations (Table 3). EGRac contributed 1% of the 275	
variance in hemoglobin concentrations in the multivariable linear regression model. RBP, 276	
ferritin, and sTfR were all predictors of hemoglobin. There was no significant interaction 277	
between country and EGRac (P = 0.75) on hemoglobin concentrations. Models for each 278	
country are shown separately (Supplemental Tables 1 and 2). When analyses were 279	
conducted by country, EGRac was negatively associated with hemoglobin concentrations 280	
in Canada, but was not a significant predictor of hemoglobin concentrations in Malaysia. 281	
Ethnicity, sTfR, and RBP were significant predictors of hemoglobin concentrations in 282	
Malaysia, whereas EGRac and sTfR remined significant predictors of hemoglobin 283	
concentrations in Canada. We further analyzed the relationship between riboflavin status 284	
and the prevalence of anemia by logistic regression. EGRac was not associated with 285	
anemia in the adjusted model (Table 4). However, deficient riboflavin status (EGRac 286	
≥1.4) was positively associated with a greater risk of anemia as shown in Table 4.  287	
 288	
DISCUSSION 289	
In this sample of healthy women of reproductive age, we found that 40% of 290	
Canadian women and 70% of Malaysian women had EGRac values ≥1.40, indicating 291	
riboflavin biomarker deficiency. We also report that EGRac was inversely correlated with 292	
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hemoglobin concentrations and that the odds of anemia were 2-fold greater in women 293	
with riboflavin biomarker deficiency (EGRac ≥1.40) than women with EGRac <1.40.  294	
The high rate of riboflavin biomarker deficiency in Canadian women was 295	
unexpected given that white wheat flour is fortified with riboflavin and the prevalence of 296	
dietary inadequacy is very low (18). Riboflavin is naturally found in grain products in 297	
small quantities, but the milling and processing of cereal grains cause the loss of many 298	
nutrients, including riboflavin. Canada has required the addition of 0.40 mg of riboflavin 299	
to each 100 g (equivalent to 4 ppm) of white flour and all foods made from white flour 300	
since 2009 (17). Our findings are consistent with Whitfield et al. (20), who reported 41% 301	
of female university students living in Vancouver (n=49, mean age= 26.3 ± 4.6 years) 302	
had deficient (EGRac ≥1.40) and 29% had suboptimal (1.30≤ EGRac <1.40) riboflavin 303	
status (20). In contrast, the finding of higher rates of riboflavin biomarker deficiency in 304	
Kuala Lumpur compared to Metro Vancouver were expected because of the assumed 305	
lower intake of riboflavin due to low dairy consumption and lack of mandatory food 306	
enrichment or fortification (21–23). Given that less than 5% of women of reproductive 307	
age in Canada had riboflavin intakes less than the EAR for riboflavin (18), the high 308	
prevalence of EGRac ≥1.4 raises the question as to whether it is the current cutoff or the 309	
EAR is set too low.  310	
We chose EGRac cutoffs that are widely used to defining riboflavin deficiency 311	
and suboptimal status (13,20,35,41,42), but there remains controversy around which 312	
EGRac cutoff is optimal. An EGRac of 1.20 suggests 20% stimulation of the enzyme and 313	
EGRac >1.20 has been considered an indication for inadequate riboflavin intake by many 314	
researchers (43–46). However, Tillotson and Baker suggested that EGRac values up to 315	
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1.30 are considered normal based on their riboflavin depletion-repletion trial conducted 316	
on n=6 adult men (47). Sadowski set an upper limit for adequate riboflavin status of 1.34 317	
based on the mean EGRac +2 SD of a group of healthy older adult men and women (aged 318	
≥ 60 years; n=927) from the Boston Nutritional Status Survey (48). Accordingly, many 319	
have considered EGRac >1.40 (2,14,49) and ≥1.40 (13,20,29,35,42) as a cutoff point for 320	
deficiency, but even higher cutoffs have been also used (12,50).   321	
 The prevalence of anemia (hemoglobin <120 g/L) in women (20-49 y) was lower 322	
in the Canadian Health Measures Survey 2009-2011 (CHMS) than our study, 3.7% 323	
compared with 7.3%, respectively (51). Likewise, the prevalence of iron deficiency, 324	
based on a low serum ferritin (<15 µg/L), was lower in the CHMS (9.1%) than our study 325	
(14.6%). Based on national data,  22.8% of Malaysian non-pregnant women (15-49 y) 326	
were anemic (hemoglobin <120 g/L) in 2015 (52), which is similar to our sample at 327	
18.1%. Mirroring our findings, rates of anemia are higher among ethnic Malays 328	
compared to Chinese Malay (53). There are no national data on iron deficiency in 329	
Malaysian non-pregnant women, but a study in Kuala Lumpur reported that 24.1% of 330	
women (18-40 y; n=135 Malays and n=130 Chinese) had depleted iron stores (serum 331	
ferritin <15 µg/L) which is comparable to our 20.8% (54).   332	
In the current study, EGRac was inversely and independently associated with 333	
hemoglobin concentrations. The relationship was significant but weak, explaining about 334	
1% of the variance, and was the third most important modifiable predictor of hemoglobin 335	
after iron indicators (ferritin and sTfR) and vitamin A (RBP concentrations). There is 336	
little published data available for comparison.  A prospective survey carried out in China 337	
(2002-2007) reported a positive association between inadequate riboflavin intake (< 338	
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Chinese EAR) (55); assessed by 3-day weighed food record) and anemia (hemoglobin 339	
<120 g/L) in women at baseline (11). Those with anemia but with riboflavin intake in the 340	
highest quartile at baseline (1.3 mg/d) were less likely to have anemia at the 5-year 341	
follow up [RR=0.52 (95%CI: 0.28, 0.98)]. However, no biochemical indicators of 342	
riboflavin status were measured in this survey. A study conducted in the UK in n=123 343	
women (aged 19-25 years), all of whom had baseline EGRac >1.40, reported a negative 344	
correlation between hemoglobin and EGRac (n=117; r= -0.22, P= 0.016) (2). The study 345	
also showed a significant improvement in riboflavin status (decreased EGRac values) 346	
after 8 weeks of riboflavin supplementation (2 or 4 mg/day) with a dose-dependent 347	
response. This improvement in riboflavin status was associated with an increase in 348	
hemoglobin concentrations, but this was observed only among women with the poorest 349	
riboflavin status at baseline (EGRac >1.65) (2). We found 1.5% and 14.8% of women 350	
above this cutoff in Canada and Malaysia, respectively.  351	
Our study had a number of strengths, including the use of a robust functional 352	
marker of riboflavin status, EGRac, and including women of different ethnicities from 353	
different countries. Moreover, we were able to adjust for a number of important 354	
nutritional and non-nutritional confounders. However, we did not  measure biomarkers of 355	
vitamin B-6, vitamin C, and zinc, which have been shown to be associated with anemia 356	
(56–58). Our use of convenience samples makes it difficult to generalize findings of this 357	
study to non-pregnant women living in Metro Vancouver and Kuala Lumpur. For 358	
example, the women were of higher education than the general population. Over 60% of 359	
our sample had obtained a bachelor’s degree or higher, compared with 39% of women 360	
aged 25-64 y in Metro Vancouver (59) and 18% of women aged 20-44 y in Selangor 361	
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state, Malaysia (60). Therefore, studies on representative samples of Canadian and 362	
Malaysian women are needed. There were very few cases of anemia (n=53) to draw 363	
definitive conclusions. Exploring the relationship between riboflavin status and anemia in 364	
populations with higher rates of anemia is warranted.   365	
In conclusion, we found high rates of suboptimal and deficient riboflavin 366	
biomarker status (EGRac ≥1.30) in women from both Canada and Malaysia with higher 367	
rates observed in Malaysian women. The findings in Canada were surprising given 368	
riboflavin fortification and the low rate of dietary riboflavin inadequacy. The unexpected 369	
higher rates of riboflavin biomarker deficiency in European than Chinese women in 370	
Canada require further research. Riboflavin status was found to be a predictor for 371	
hemoglobin concentrations, albeit to a lesser extent than iron or vitamin A. Although 372	
EGRac is widely recognized as the gold standard biomarker for assessing riboflavin 373	
status, standardized protocols and cutoffs are required to allow for valid comparisons 374	
between different populations.  375	
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TABLE 1 Characteristics of women aged 19-45 years in Vancouver, Canada, and Kuala Lumpur, Malaysia1 















Age, years  27.6 ± 6.4  28.7 ± 6.0  26.2 ± 6.6 0.004   27.3 ± 5.3 28.3 ± 5.4  26.3 ± 5.1 0.006 0.72 
Parity (≥1 child born) 14 (6.8)  8 (7.3) 6 (6.3) 1.00  31 (14.8) 24 (23.1) 7 (6.7) 0.001 0.011 
Smokers  2 (<1) 2 (1.8) 0  0.50  2 (0.96) 0  2 (1.9) 0.24 1.00 
Education    <0.001     0.34 0.43 
Secondary or less 28 (13.6) 5 (4.6) 23 (24.0)   29 (13.9) 18 (17.5) 11 (10.5)   
Some post-Secondary  45 (21.8) 19 (17.3) 26 (27.1)   35 (16.8) 17 (16.5) 18 (17.1)   
Bachelor’s or higher 133 (64.6) 86 (78.2) 47 (49.0)   144 (69.2) 68 (66.0) 76 (72.4)   
BMI, kg/m2 22.5 ± 3.9 23.1 ± 4.1 21.7 ± 3.6 0.008  23.6 ± 5.0 25.1 ± 6.0 22.1 ± 3.3 <0.001 0.021 
Overweight/obesity ≥25 41 (20.0) 26 (23.6) 15 (15.6) 0.17  58 (27.8) 43 (41.4) 15 (14.3) <0.001 0.039 
Waist circumference, cm 73.0 ± 9.8 74.4 ± 10.5 71.4 ± 8.6 0.026  74.7 ± 11.2 77.0 ± 13.3 72.5 ± 8.0 0.004 0.10 
Waist circumference ≥80 cm 34 (16.6) 19 (17.3) 15 (16.8) 0.85  50 (23.9) 35 (33.7) 15 (14.3) 0.001 0.07 
Inflammation           
Acute, CRP >5 mg/L  11 (5.3) 8 (7.3) 3 (3.1) 0.23  17 (8.1) 15 (14.3) 2 (1.9) 0.002 0.33 
Chronic, AGP >1 g/L  4 (1.9) 4 (3.6) 0 0.13  5 (2.4) 4 (3.8) 1 (<1.0) 0.37 1.00 
1Values are presented as means±SDs or n (%). Data are analyzed by Fisher’s exact test (proportion) or two-sample t-test (continuous). AGP, α-1 acid 













TABLE 2 Anemia and micronutrients status of women aged 19–45 years in Malaysia and Canada1 

















Hemoglobin, g/L2 130.9 ± 8.4 131.4 ± 9.2 130.2 ± 7.5 0.29  129.4 ± 12.2 127.2 ± 12.3 131.5 ± 11.8 0.011 0.15 
Anemia (hemoglobin <120 g/L)3 15 (7.3) 7 (6.4) 8 (8.3) 0.60  38 (18.1) 24 (22.9) 14 (13.3) 0.11 0.001 
Microcytic anemia (hemoglobin 
<120 g/L and MCV <80 fL)3 7 (3.4) 2 (1.8) 5 (5.2) 0.26  26 (12.5) 17 (16.5) 9 (8.6) 0.096 0.001 
EGRac, ratio2 1.38 ± 0.11 1.40 ± 0.10 1.36 ± 0.13 0.022  1.49 ± 0.17 1.52 ± 0.17 1.46 ± 0.15 0.005 <0.001 
Adequate, EGRac <1.33 58 (28.2) 17 (15.5) 41 (42.7) <0.001  20 (9.5) 8 (7.6) 12 (11.4) 0.021 <0.001 
Suboptimal, 1.3≤ EGRac <1.43 66 (32.0) 44 (40.0) 22 (22.9)   40 (19.0) 13 (12.4) 27 (25.8)   
Deficient, EGRac ≥1.43 82 (39.8) 49 (44.5) 33 (34.4)   150 (71.4) 84 (80.0) 66 (62.9)   
Serum ferritin, µg/L4  36.9 (38.9) 34.1 (32.1) 38.9 (50.9) 0.31  38.4 (49.4) 40.4 (52.2) 37.1 (44.1) 0.22 0.73 
Ferritin <15 µg/L3 30 (14.6) 14 (12.7) 16 (16.7) 0.44  43 (20.5) 18 (17.1) 25 (23.8) 0.31 0.12 
Serum sTfR, mg/L4  4.43 (1.42) 4.35 (1.29) 4.58 (1.55) 0.19  5.08 (1.99) 5.09 (1.98) 4.89 (1.97) 0.34 <0.001 
 sTfR >8.3 mg/L3 8 (3.9) 2 (1.8) 6 (6.3) 0.15  19 (9.1) 9 (8.6) 10 (9.5) 1.00 0.045 
Plasma vitamin B-12, pmol/L4 307.5 (147.0) 254.0 (137) 352.0 (135.5) <0.001  360.0 (152.0) 372.0 (167.0) 336.0 (128.0) 0.017 <0.001 
Deficiency, <148 pmol/L3 2 (<1) 2 (1.8) 0 (0) 0.50  1 (<1) 0 (0) 1 (<1.0) 1.00 0.620 
Marginal, 148-220 pmol/L 3 41 (19.9) 36 (32.7) 5 (5.2) <0.001  7 (3.3) 1 (1.0) 6 (5.7) 0.07 <0.001 
Plasma folate, nmol/L4 31.5 (15.5) 31.5 (17.6) 31.6 (14.8) 0.73  13.7 (8.4) 11.8 (6.5) 16.6 (9.8) <0.001 <0.001 
Folate >45.3 nmo/L3 38 (18.5) 20 (18.2) 18 (18.8) 1.00  2 (1.0) 1 (1.0) 1 (1.0) 1.00 <0.001 
Serum RBP, μmol/L2 1.8 ± 0.5 1.9 ± 0.5 1.6 ± 0.4 <0.001  1.4 ± 0.3 1.4 ± 0.3 1.3 ± 0.3 0.30 <0.001 
RBP <7 μmol/L3 0.00 0.00 0.00 1.00  1 (<1) 1 (<1) 0.00 1.00 1.00 
1Data are analyzed by two-sample t-test or Wilcoxon rank-sum test (continuous) and Fisher’s exact test (proportions). MCV, mean corpuscular 
volume; EGRac, erythrocyte glutathione reductase activity coefficient; sTfR, soluble transferrin receptor, RBP, retinol binding protein. 
2Values are means±SDs. 3Values are n (%). 4Values are medians (IQRs).  
5Ferritin and RBP were adjusted for levels of subclinical inflammation by using AGP and CRP biomarkers (33,34)
	 30	
TABLE 3 Association between hemoglobin concentrations and riboflavin status (EGRac) 1 
 B (95% CI) Standardized coefficient β  P 
EGRac -7.02 (-13.30, -0.74) -0.10  0.029 
Age (y) -0.12 (-0.30, 0.06) -0.07  0.20 
Parity (Yes versus No) -0.32 (-3.82, 3.18) -0.01  0.86 
Ethnicity    
European Reference   
C-Chinese -0.57 (-3.31, 2.18) -0.02 0.69 
Malay 0.47 (-2.97, 3.91) 0.02 0.79 
M-Chinese 4.47 (1.35, 7.58) 0.18 0.005 
Folate (nmol/L) 0.03 (-0.05, 0.11) -0.04  0.51 
Vitamin B-12 (pmol/L) 0.01 (0.00, 0.01) 0.08 0.09 
Ferritin (µg/L)2 0.03 (0.00, 0.06) 0.09  0.035 
sTfR (mg/L) -1.60 (-1.94, -1.27) -0.42  <0.001 
RBP (μmol/L)2 5.03 (2.73, 7.34) 0.22  <0.001 
1Multiple linear regression was used with hemoglobin concentrations (g/L) as a dependent variable; n=415. Model 
R2= 0.29 and adjusted R2= 0.27; EGRac contributed to 1% of the variance in hemoglobin concentrations; the 
correlation matrix and variance inflation factors showed no signs of multicollinearity between variables included in 
the model. EGRac, erythrocyte glutathione reductase activity coefficient; C-Chinese, Canadian Chinese; M-Chinese, 
Malaysian Chinese; sTfR, soluble transferrin receptor; RBP, retinol binding protein.  
2Ferritin and RBP were adjusted for levels of subclinical inflammation by using AGP and CRP biomarkers (33,34)
	 31	
TABLE 4 Association between anemia and riboflavin status (EGRac) and deficiency1 
Anemia OR SE z P 95% CI 
Model 1: EGRac2 6.03 6.37 1.70 0.09 (0.76, 47.86) 
Model 2: Riboflavin deficiency3 2.38 0.96 2.14 0.032 (1.08, 5.27) 
1Logistic regression was used with anemia (yes/no) as an outcome variable and both models were adjusted for 
concentrations of folate, vitamin B-12, sTfR, and RBP; n=416. EGRac, erythrocyte glutathione reductase activity 
coefficient. 
2EGRac was added to the model as a continuous variable; Model Pseudo R2= 0.27; An OR of 6.03 indicates that the 
odds of being anemic are 6.03 times higher with one-unit increase in EGRac after holding vitamin B-12, folate, 
sTfR, and RBP concentrations at fixed values. 
3Riboflavin deficiency (EGRac ≥1.4) was added to the model as a categorical variable and EGRac <1.4 was the 
reference category; Model Pseudo R2= 0.27. An OR=2.38 indicates that the odds of anemia in women with 
riboflavin deficiency (EGRac ≥1.4) is 2.38 times that of women with EGRac <1.4 after holding vitamin B-12, folate, 
sTfR, and RBP concentrations at fixed values. 
 
